Notably, IKBKE has emerged as a therapeutic target for advanced prostate cancer due to its role in inhibiting resistance to androgen receptor-targeted therapies, as well as its effects on proliferation, migration, and colony formation (33–35). This evidence concerns the gene AR and prostate cancer.